Nobio Ltd., innovators in antimicrobial nanotechnologies, announced that John Scott has joined the company as Chief Commercial Officer. Mr. Scott, an experienced executive leader in the dental industry, will head up the company’s North American operations supporting Nobio’s award winning infinix family of antimicrobial composites.
“John is uniquely qualified to help Nobio fully realize the potential of our antimicrobial technology platform,” said Ronen Raz, Nobio Chief Operating Officer. The infinix line of restoratives is the first use case of Nobio’s patented QASiTM antimicrobial particle technology, that is ultimately applicable to a wide range of dental products. “We are fortunate to have found a leader with John’s dental industry experience and track record of success.”
Mr. Scott is a fifteen-year dental industry veteran, having earned progressively senior positions in sales, marketing, and general management. His roles include Senior Vice President for Zyris/Isolite Systems, President & Chief Marketing Officer for Air Techniques, and Vice President/Business Unit Manager for Pentron Clinical.
“The Nobio technology platform has the promise of reducing the risk of secondary caries,” said Scott. As the industry’s only FDA cleared antibacterial composite, infinix has been shown to significantly reduce demineralization, which is part of the decay process. The infinix line of advanced restorative materials was also recently selected as a Cellerant Best of Class Technology Award recipient for the second year in a row.
“It’s incredibly exciting to join the Nobio team and help bring this important technology to the dental community,” Scott continued. “We invite all dentists and dental professionals to join us at the upcoming ADA Smilecon conference to learn more about Nobio technology, infinix dental products, and to celebrate the Best of Class Award.”
Nobio is a material sciences company that redefines the field of antimicrobial products and solutions with its long-lasting, safe, and highly active novel particle technology. They have developed and are commercializing infinix, the first line of dental materials with its revolutionary antimicrobial technology to address recurrent caries, which is among the main causes of dental treatment failure and tooth loss. They are also working with leading medical, dental, consumer, and industrial manufacturers to bring long-lasting antimicrobial properties to a wide range of medical devices and applications.